Flputnam Investment Management Co. Raises Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Flputnam Investment Management Co. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 94.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 67,484 shares of the medical research company’s stock after purchasing an additional 32,693 shares during the quarter. Flputnam Investment Management Co.’s holdings in Thermo Fisher Scientific were worth $33,834,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Elyxium Wealth LLC grew its holdings in Thermo Fisher Scientific by 1.9% during the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock worth $613,000 after acquiring an additional 20 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. grew its stake in Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock worth $1,436,000 after purchasing an additional 20 shares in the last quarter. Princeton Capital Management LLC increased its holdings in Thermo Fisher Scientific by 2.4% in the fourth quarter. Princeton Capital Management LLC now owns 922 shares of the medical research company’s stock valued at $534,000 after buying an additional 22 shares during the last quarter. Finally, TCI Wealth Advisors Inc. raised its stake in Thermo Fisher Scientific by 5.4% during the first quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock valued at $212,000 after buying an additional 22 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Piper Sandler raised their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Finally, HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price target for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Trading Down 1.4%

NYSE:TMO opened at $621.87 on Friday. The firm has a market capitalization of $229.94 billion, a P/E ratio of 33.45, a P/E/G ratio of 2.53 and a beta of 0.85. The business has a 50 day simple moving average of $558.64 and a 200 day simple moving average of $512.08. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the company earned $4.28 earnings per share. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 73,768 shares of company stock worth $44,122,820 in the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.